ERCC2 and cancer: Indeed, in our cohort, we found a 2.2-fold difference in mutation load between active and inactive TADs in sporadic cancers, but it was noticeably decreased in XP-C (1.4-fold) cancers and was virtually absent in XP-A (1.05-fold) and XP-D (1.09-fold; Fig. 2b).